Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
4.700
-0.100 (-2.08%)
Jun 27, 2025, 4:00 PM - Market closed
Y-mAbs Therapeutics Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Y-mAbs Therapeutics stock ranges from a low of $7.00 to a high of $26. The average analyst price target of $17.55 forecasts a 273.40% increase in the stock price over the next year.
Price Target: $17.55 (+273.40%)
Analyst Consensus: Buy
* Price targets were last updated on May 29, 2025.
Analyst Ratings
The average analyst rating for Y-mAbs Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $20 → $15 | Buy | Maintains | $20 → $15 | +219.15% | May 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +134.04% | May 19, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +197.87% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $21 → $20 | Buy | Maintains | $21 → $20 | +325.53% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $12 | Strong Buy | Maintains | $22 → $12 | +155.32% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
84.06M
from 87.69M
Decreased by -4.13%
Revenue Next Year
96.80M
from 84.06M
Increased by 15.15%
EPS This Year
-1.02
from -0.67
EPS Next Year
-1.11
from -1.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 90.3M | 136.3M | 145.2M | ||
| Avg | 84.1M | 96.8M | 109.8M | ||
| Low | 76.5M | 84.2M | 94.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0% | 62.1% | 50.0% | ||
| Avg | -4.1% | 15.2% | 13.4% | ||
| Low | -12.7% | 0.1% | -2.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.84 | -0.96 | -0.40 | ||
| Avg | -1.02 | -1.11 | -1.09 | ||
| Low | -1.14 | -1.40 | -1.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.